SCHEDULE 13G/A: Brio Capital Master Fund Ltd. and Brio Capital Management LLC Maintain 9.99% Stake in Sigyn Therapeutics

Brio Capital Master Fund Ltd. and Brio Capital Management LLC have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Sigyn Therapeutics, Inc., totaling 158,932 shares as of November 19, 2024.

Summary

• Brio Capital Master Fund Ltd. and Brio Capital Management LLC jointly filed an Amendment No. 7 to Schedule 13G regarding their beneficial ownership in SIGYN THERAPEUTICS, INC.
• As of November 19, 2024, the Reporting Persons beneficially own an aggregate of 158,932 shares of Sigyn Therapeutics' common stock.
• This ownership represents 9.99% of the 1,605,378 shares of common stock outstanding as reported by the Issuer on November 19, 2024.
• The beneficial ownership includes 97,866 shares of common stock and additional shares issuable upon the exercise of Warrants, Convertible Notes, and Convertible Preferred Shares.
• Notably, $8,800 in face value of Convertible Notes were purchased in the quarter ended December 31, 2024.
• The Warrants, Convertible Notes, and Convertible Preferred Shares are structured such that they are not exercisable if the holder would beneficially own in excess of 9.99% of the outstanding shares.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory disclosure of beneficial ownership. It does not contain information that would inherently lead to a strong positive or negative sentiment regarding the company's performance or prospects.

Positives

• The continued significant stake by Brio Capital Master Fund Ltd. and Brio Capital Management LLC may signal ongoing investor confidence in Sigyn Therapeutics, Inc.

Negatives

• The beneficial ownership cap of 9.99% limits the extent to which Brio Capital can convert its convertible instruments, potentially capping their upside from these specific holdings if the company's stock price significantly increases.
• The filing explicitly states the securities were not acquired for the purpose of changing or influencing control, indicating a passive investment approach from this significant holder.

Risks

• The beneficial ownership limitation of 9.99% on the exercise of Warrants, Convertible Notes, and Convertible Preferred Shares could restrict Brio Capital's ability to fully realize potential gains from these instruments if the company's share price appreciates significantly and they are unable to convert due to the cap.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Sigyn Therapeutics, Inc. or the Reporting Persons regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It reflects an investor's position rather than a specific industry trend or competitive development.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming Brio Capital's continued passive investment position.

Key Dates

Keywords

SIGYN THERAPEUTICS, Brio Capital, Schedule 13G, beneficial ownership, common stock, convertible notes, warrants, convertible preferred shares, SEC filing, investment, equity stake